Oberhaching, April 2022 To whom it may concern We hereby wish to inform you about a change in personnel at Bendalis GmbH and Lyomark Pharma GmbH. Mr Parvany will leave the company on 31 March 2022. Mr Parvany has been involved in both companies since 2012, joining as head of sales and marketing and becoming … Weiterlesen …
Oberhaching, 21 September 2021 To whom it may concern We hereby wish to inform you about a change in personnel at Bendalis GmbH and Lyomark Pharma GmbH. Malik Malocho will leave the companies on 30 September 2021. He has been involved in both companies since 2006, joining as head of supply chain and becoming managing … Weiterlesen …
BERLIN / MUNICH – 25 November 2019 – The global pharmaceutical company and service partner Inceptua Group (previously Multipharma GmbH) and Bendalis GmbH – German manufacturer of generic oncology drugs and special therapeutic agents, today announce the signing of an exclusive clinical trial supply agreement for oncology generics. Through this agreement Inceptua becomes the exclusive … Weiterlesen …
We would like to thank all partners and interested parties for the many inspiring discussions during the CPhI in Frankfurt. We hope that the days were just as successful for you in Frankfurt as they were for us. We look forward to seeing you all again next year in Milan from the 13th to the 15th … Weiterlesen …
From 5th to 7th November 2019, we will be showcasing our products and services at the CPhI Worldwide in Frankfurt. We look forward to seeing you at our booth (92F23). See you in Frankfurt! The Bendalis Team
We welcome you to arrange a meeting with us. Please contact us by email or phone and arrange a meeting. We invite you at the Lyomark Pharma booth 14.1 D92. Lyomark Pharma GmbH is our sister company and supplies sterile lyophilised and liquid products. See you in Madrid! The Bendalis Team
A change at the top of Bendalis GmbH: As of 1 July 2017, Christian Parvany (39) will join the management team of the company as Dr Helmut Wolf ends his tenure as managing director of Bendalis GmbH, a position he has held for more than ten years. Dr Wolf will remain at the company as … Weiterlesen …
The role of endogenous cannabinoids in skin and mucosal inflammations Damage to the skin and mucous membranes is one of the most common side effects related to cancer therapy. It affects not only a patient’s quality of life, but also the success of treatment. The aim of cancer treatments is to slow or even stop … Weiterlesen …
This is what to expect from AgainLife medical devices when it comes to minimising or even preventing the side effects of chemotherapy or radiotherapy. The proven and patented active substance adelmidrol is what makes the AgainLife range so remarkable – products that are now available to pharmacies from Bendalis GmbH in Oberhaching. www.againlife.de Adelmidrol is … Weiterlesen …
In 2009, Bendalis GmbH entered into partnership with EUSA Pharma, which has operations in the USA and Europe, for distribution of Caphosol®. Since the beginning of 2011, Bendalis GmbH has had a copromotion agreement with Riemser Arzneimittel AG for ALOXI® (palonosetron), an innovative 5-HT3 receptor antagonist for prophylaxis of chemotherapy-induced nausea and vomiting (CINV).